Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6979241 | 0.84 | TDP1 (0.36) | POLBLTA4HHSD17B10HRH3 | |
| SCHEMBL15865996 | 0.82 | HRH3 (0.38) | SMN1; SMN2HRH3 | |
| SCHEMBL6956360 | 0.80 | SIGMAR1 (0.40) | SIGMAR1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL13204869 | 0.80 | SMN1; SMN2 (0.33) | SIGMAR1POLBSMN1; SMN2CXCR4 | |
| SCHEMBL13204962 | 0.80 | SMN1; SMN2 (0.33) | SIGMAR1POLBSMN1; SMN2CXCR4 | |
| SCHEMBL6978377 | 0.79 | HDAC3 (0.46) | SIGMAR1POLBSMN1; SMN2HRH3 | |
| SCHEMBL6979248 | 0.77 | HPGD (0.36) | MEN1KMT2A | |
| SCHEMBL13017472 | 0.76 | SIGMAR1 (0.45) | SIGMAR1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL6979146 | 0.74 | KDM4E (0.38) | SMN1; SMN2HRH2HRH1HRH3 | |
| SCHEMBL6976370 | 0.74 | DRD3 (0.48) | SIGMAR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1854789-B1 | QUINAZOLINE DERIVATIVE HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | ERBB2, EGFR, ABL1 | SIGMAR1 98/4885POLB 3854/4885SMN1; SMN2 4182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.